Literature DB >> 3355415

The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on postsurgical blood-aqueous barrier.

A J Flach1, M C Kraff, D R Sanders, L Tanenbaum.   

Abstract

Anterior chamber fluorophotometry was performed after the oral administration of fluorescein sodium in patients undergoing extracapsular cataract extraction and posterior chamber intraocular lens insertion before and after surgery. The administration of 0.5% ketorolac tromethamine solution (ketorolac solution) eye drops before and after surgery decreased the breakdown of the blood-aqueous barrier as compared with 0.1% dexamethasone sodium phosphate solution (dexamethasone solution) eye drops at each period, as measured by fluorophotometry. A single injection below Tenon's capsule of a short-acting corticosteroid had been given to each patient at the end of each surgical procedure. Slit-lamp observations of postoperative ocular inflammation were not different between treatment groups. Both ketorolac and dexamethasone solutions were well tolerated by patients. Ketorolac solution was more effective than dexamethasone solution in facilitating reestablishment of the blood-aqueous barrier after surgery, as measured by fluorophotometry, and was equal to dexamethasone solution as observed by slit-lamp observations. This study suggests that ketorolac ophthalmic solution may be effective and safe as a nonsteroidal anti-inflammatory agent for topical use after cataract surgery and intraocular lens implantation in place of topically administered corticosteroids.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3355415     DOI: 10.1001/archopht.1988.01060130526028

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  14 in total

Review 1.  The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery.

Authors:  A J Flach
Journal:  Trans Am Ophthalmol Soc       Date:  1998

Review 2.  Locally administered ocular corticosteroids: benefits and risks.

Authors:  Charles N J McGhee; Simon Dean; Helen Danesh-Meyer
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

3.  In vivo ocular availability of ketorolac following ocular instillations of aqueous, oil, and ointment formulations to normal corneas of rabbits: a technical note.

Authors:  Manjusha Malhotra; Dipak K Majumdar
Journal:  AAPS PharmSciTech       Date:  2005-10-24       Impact factor: 3.246

4.  Aqueous, oil, and ointment formulations of ketorolac: efficacy against prostaglandin E2-induced ocular inflammation and safety: a technical note.

Authors:  Manjusha Malhotra; Dipak K Majumdar
Journal:  AAPS PharmSciTech       Date:  2006       Impact factor: 3.246

5.  Diffusion coefficient through the blood-aqueous barrier using a standard protocol.

Authors:  J van Best; J B del Castillo; M Diestelhorst; B Heintz; E Leite; L F Liesenborghs; R Schalnus
Journal:  Br J Ophthalmol       Date:  1996-04       Impact factor: 4.638

Review 6.  The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology.

Authors:  P Koay
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

7.  Conventional routine clinical review may not be necessary after uncomplicated phacoemulsification.

Authors:  B D Allan; R M Baer; P Heyworth; I G Duguid; J K Dart
Journal:  Br J Ophthalmol       Date:  1997-07       Impact factor: 4.638

Review 8.  Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  M M Buckley; R N Brogden
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

9.  Diclofenac prevents temporal increase of intraocular pressure after uneventful cataract surgery with longer operation time.

Authors:  Masahiko Shimura; Toru Nakazawa; Kanako Yasuda; Takashi Shiono; Kohji Nishida
Journal:  Clin Ophthalmol       Date:  2009-06-02

10.  Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction.

Authors:  Ester Carreño; Alejandro Portero; David J Galarreta; José M Herreras
Journal:  Clin Ophthalmol       Date:  2012-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.